Straits Times Index
3,303.19 +10.26 (+0.31%) S&P 500
5,156.68 +28.89 (+0.56%) Dow
38,743.27 +67.59 (+0.17%) Nasdaq
16,255.23 +98.90 (+0.61%) Bitcoin USD
63,071.61 -996.94 (-1.56%) CMC Crypto 200
1,371.06 +58.43 (+4.45%)
Dr. Reddy's Laboratories Limited (RDY)
| Previous close | 75.21 |
| Open | 74.95 |
| Bid | 75.01 x 800 |
| Ask | 75.17 x 1000 |
| Day's range | 74.92 - 75.19 |
| 52-week range | 53.12 - 77.72 |
| Volume | |
| Avg. volume | 186,368 |
| Market cap | 12.67B |
| Beta (5Y monthly) | 0.34 |
| PE ratio (TTM) | 20.04 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 0.49 (0.65%) |
| Ex-dividend date | 07 Jul 2023 |
| 1y target est | N/A |
- Business Wire
Dr. Reddy's Laboratories Announces the Launch of Doxycycline Capsules, 40 mg* in the U.S.
HYDERABAD, India, May 03, 2024--Dr. Reddy's Laboratories announces the launch of Doxycycline Capsules, 40 mg* in the U.S. market.
- GlobeNewswire
Pharmazz Inc. and Dr. Reddy's Laboratories have entered into a licensing agreement to market Centhaquine (Lyfaquin) as a resuscitative agent for hypovolemic shock in India
Centhaquine is a first-of-its-kind resuscitative agent to treat hypovolemic shock by increasing stroke volume and cardiac output due to an increase in (preload) venous blood return to the heart and a decrease in (afterload) due to arterial dilatationIndia is the first global territory where Centhaquine is being launched immediately WILLOWBROOK, Ill., March 22, 2024 (GLOBE NEWSWIRE) -- Pharmazz, Inc. ("Pharmazz"), a biopharmaceutical company developing and commercializing drug products to treat c
- Business Wire
Dr. Reddy's Laboratories launches Versavo® (bevacizumab) in the UK
HYDERABAD, India, March 19, 2024--Dr. Reddy’s Laboratories Ltd., a global pharmaceutical company, announced the launch of Versavo® (bevacizumab) in the United Kingdom (UK).
